Imaging Guidelines for Special Patient Populations
Introduction to Acoustic Neuromas
- Acoustic neuromas, also known as vestibular schwannomas, are benign tumors that arise from the vestibular nerve, with an estimated incidence of 1.3 per 100,000 people per year, as reported by the National Institute of Neurological Disorders and Stroke 1
- Approximately 4-6% of vestibular schwannomas are associated with Neurofibromatosis Type 2 (NF2), and histological variants, such as melanotic and cellular schwannomas, have higher recurrence rates, with malignant transformation possible in melanotic schwannomas, as noted by the National Institute of Neurological Disorders and Stroke 2, 3
Diagnosis and Imaging
- MRI with gadolinium enhancement is the gold standard for diagnosis of acoustic neuromas, with specific protocols including T1-weighted sequences before and after gadolinium, high-resolution T2-weighted sequences, and diffusion-weighted imaging, as recommended by the American Association of Neurological Surgeons and the American Academy of Neurology 4, 2
- High-resolution T2-weighted sequences, such as 3D constructive interference in steady state (CISS) or FIESTA sequences, are excellent for visualizing the relationship between the tumor and adjacent cranial nerves, and can help identify the course of the facial nerve, as recommended by the American Association of Neurological Surgeons 4
- Diffusion-weighted imaging (DWI) helps differentiate acoustic neuromas from other cerebellopontine angle masses, with acoustic neuromas typically demonstrating reduced diffusion due to high cellularity, according to the National Comprehensive Cancer Network 5
- Audiometric evaluation is essential to document the degree and type of hearing loss, typically showing asymmetric hearing loss with poor speech discrimination, and is recommended by the American Academy of Otolaryngology-Head and Neck Surgery to document the degree and type of hearing loss when acoustic schwannoma is suspected, with evidence level III and recommendation level C 2, 3
- Auditory brainstem response (ABR) is highly sensitive (90.5%) even in patients with normal hearing, as noted by the National Institute of Neurological Disorders and Stroke 1
Treatment Options
- Observation with regular follow-up is recommended for small, asymptomatic tumors, as suggested by the American Association of Neurological Surgeons 6
- Stereotactic radiosurgery is an option for patients with significant comorbidities, and is recommended for NF2 patients whose vestibular schwannomas are enlarging and/or causing hearing loss, with single fraction doses <13 Gy recommended to minimize cranial nerve deficits, as recommended by the American Association of Neurological Surgeons and the European Association of Neuro-Oncology (EANO) guidelines 6, 2
- Fractionated radiotherapy or hypofractionated Stereotactic Radiotherapy (SRT) using up to 10 fractions may be considered for larger tumors, as recommended by the European Association of Neuro-Oncology (EANO) guidelines 2
- Bevacizumab and Lapatinib may be considered for reducing vestibular schwannoma size and improving hearing in NF2 patients, as recommended by the American Association of Neurological Surgeons 7
- Aspirin may be considered for patients undergoing observation of vestibular schwannomas, as recommended by the American Association of Neurological Surgeons 7
- Immediate surgical intervention is recommended for large tumors with brainstem compression, existing facial nerve palsy, and significant growth, prioritizing facial nerve preservation, as recommended by the American Academy of Neurological Surgeons 2
Surgical Considerations
- A retrosigmoid approach is suggested for large tumors, providing excellent visualization of the brainstem and cranial nerves, and allowing access to large tumors with brainstem compression, as recommended by the American Academy of Neurological Surgeons 2
- Near-total resection rather than gross total resection is recommended to prioritize facial nerve preservation, with intraoperative monitoring including facial nerve monitoring, somatosensory evoked potentials, and electromyography of lower cranial nerves, as recommended by the American Academy of Neurological Surgeons 2
- Optimal surgical resection should be offered when technically feasible with low risk of permanent postoperative functional deterioration, as recommended by the British Journal of Cancer 8
Post-Treatment Monitoring
- Post-surgical MRI within 48-72 hours is recommended to document the extent of resection, and regular MRI surveillance every 6 months for the first 2 years and annually thereafter for at least 5 years, as recommended by the American Association of Neurological Surgeons 4
- Annual MRI and audiometry for 5 years, with extended intervals thereafter if stable, are recommended for post-treatment monitoring, with approximately 50% of tumors potentially growing over a 5-year period, as recommended by the Neuro-Oncology guidelines and the American Academy of Neurology 2
- Long-term monitoring is essential, as approximately 7.2% of tumors may exhibit growth after a stable period of 5 years, highlighting the need for long-term monitoring, as recommended by the Neuro-Oncology guidelines and the American Academy of Neurology 2